Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Announces Renewal Of Approval for Autism Spectrum Disorder Trial
Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 31, 2024
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Submits IND for Phase IIb Trial of SCI-110 for Tourette Syndrome
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Product Name : SCI-110
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Enrolls First Five Patients in Trial for SCI-210 Treatment
Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Enrolls First Patient for Clinical Trial for Children with ASD
Details : SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 03, 2024
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Initiates Patient Recruitment for Clinical Trial with SCI-210 in ASD Children
Details : SCI-210 (cannabidiol) is a combination of cannabidiol and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated in clinical trials for the treatment of autism spectrum disorder.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 29, 2023
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBC-Ab002 is a novel, fully human anti-PD-L1 monoclonal antibody designed to harness the peripheral immune system to rewire brain/immune communication and protect the brain from functional loss in the patients with alzheimer's disease.
Product Name : IBC-Ab002
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2023
Details : The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.
Product Name : IBC-Ab002
Product Type : Antibody
Upfront Cash : Undisclosed
January 09, 2020